2327 GMT [Dow Jones]--Cochlear's lineup of new products turns UBS analysts bullish on the stock. They upgrade their recommendation on the hearing-tech manufacturer to buy from neutral, telling clients in a note that they expect its new implant portfolio to deliver global market share gains and 10% compound annual revenue growth from implants over the next three years. They also see services revenue rising 40% over three years from a higher installed base and as customers replace processors. UBS raises its target price 14% to A$325.00. Shares are at A$281.66 ahead of the open. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
June 17, 2025 19:34 ET (23:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。